1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Diarrhea - Pipeline Review, H1 2016

Diarrhea - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 186 pages

Diarrhea - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Diarrhea - Pipeline Review, H1 2016’, provides an overview of the Diarrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Diarrhea
- The report reviews pipeline therapeutics for Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diarrhea therapeutics and enlists all their major and minor projects
- The report assesses Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diarrhea

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diarrhea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Diarrhea - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diarrhea Overview 8
Therapeutics Development 9
Pipeline Products for Diarrhea - Overview 9
Pipeline Products for Diarrhea - Comparative Analysis 10
Diarrhea - Therapeutics under Development by Companies 11
Diarrhea - Therapeutics under Investigation by Universities/Institutes 14
Diarrhea - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Diarrhea - Products under Development by Companies 18
Diarrhea - Products under Investigation by Universities/Institutes 21
Diarrhea - Companies Involved in Therapeutics Development 22
A. Menarini Industrie Farmaceutiche Riunite Srl 22
Ache Laboratorios Farmaceuticos S/A 23
Actelion Ltd 24
Aegis Therapeutics, LLC 25
Akthelia Pharmaceuticals Limited 26
AlbireoPharma 27
Allergan Plc 28
Anatara Lifesciences Limited 29
Ardelyx, Inc. 30
Assembly Biosciences, Inc. 31
Chiesi Farmaceutici SpA 32
Cosmo Pharmaceuticals S.p.A 33
DesignMedix, Inc. 34
DiscoveryBiomed, Inc. 35
Genexine, Inc. 36
GlaxoSmithKline Plc 37
GP Pharm, S.A. 38
Helsinn Healthcare S.A. 39
Intercept Pharmaceuticals, Inc. 40
Merck and Co., Inc. 41
Mucosis B.V. 42
Nippon Shinyaku Co., Ltd. 43
Novartis AG 44
Pfizer Inc. 45
Prokarium Limited 46
Protagonist Therapeutics Inc. 47
Rebiotix Inc. 48
RxBio, Inc. 49
Sanofi Pasteur SA 50
Scandinavian Biopharma Holding AB 51
Shire Plc 52
Sigmoid Pharma Limited 53
Summit Therapeutics Plc 54
Synthetic Biologics, Inc. 55
Syntiron LLC 56
Diarrhea - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Target 58
Assessment by Mechanism of Action 60
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 66
ABM-101 - Drug Profile 66
ACE-527 - Drug Profile 67
ACE-920 - Drug Profile 69
ACH-04 - Drug Profile 70
AKT-10081 - Drug Profile 71
ASP-7147 - Drug Profile 72
cadazolid - Drug Profile 73
Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile 74
cholestyramine - Drug Profile 76
Clostridium difficile vaccine - Drug Profile 77
crofelemer DR - Drug Profile 78
Drug for Diarrhea - Drug Profile 80
elsiglutide - Drug Profile 81
eluxadoline - Drug Profile 82
Escherichia coli vaccine - Drug Profile 84
ETEC vaccine - Drug Profile 85
ETEC vaccine - Drug Profile 86
Etvax - Drug Profile 87
fidaxomicin - Drug Profile 89
GVXNSD-133 - Drug Profile 93
GXG-8 - Drug Profile 94
Helicobacter pylori [strain Hel-305] (multivalent) vaccine - Drug Profile 95
ibodutant - Drug Profile 96
IMSUTMR-1501 - Drug Profile 97
infectious diarrhea [serotype H11] vaccine - Drug Profile 98
obeticholic acid - Drug Profile 99
octreotide acetate - Drug Profile 102
octreotide acetate MAR - Drug Profile 103
Peptide to Activate NHE-3 for Diarrhea - Drug Profile 104
PF-06425090 - Drug Profile 105
prulifloxacin - Drug Profile 106
PZ-7475 - Drug Profile 108
RBX-2660 - Drug Profile 109
RDX-009 - Drug Profile 111
Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 112
Recombinant Proteins for Infectious Diarrhea - Drug Profile 114
ridinilazole - Drug Profile 115
rifamycin CR - Drug Profile 117
Rx-100 - Drug Profile 119
Small Molecule to Block CFTR for Diarrhoea - Drug Profile 121
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 122
Small Molecules for Microbial Infections - Drug Profile 123
Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea - Drug Profile 124
Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile 125
surotomycin - Drug Profile 126
SYN-004 - Drug Profile 127
Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea - Drug Profile 128
Typhetec - Drug Profile 129
Vaccine 1 for Diarrhea - Drug Profile 130
Vaccine 2 for Diarrhea - Drug Profile 131
Vaccine for Traveler's Diarrhea - Drug Profile 132
Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile 133
VP-20621 - Drug Profile 134
Yersinia pestis vaccine - Drug Profile 135
Diarrhea - Recent Pipeline Updates 136
Diarrhea - Dormant Projects 171
Diarrhea - Discontinued Products 174
Diarrhea - Product Development Milestones 175
Featured News and Press Releases 175
Appendix 181
Methodology 181
Coverage 181
Secondary Research 181
Primary Research 181
Expert Panel Validation 181
Contact Us 181
Disclaimer 182

List of Tables
Number of Products under Development for Diarrhea, H1 2016 13
Number of Products under Development for Diarrhea - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Development by Companies, H1 2016 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2016 18
Comparative Analysis by Late Stage Development, H1 2016 19
Comparative Analysis by Clinical Stage Development, H1 2016 20
Comparative Analysis by Early Stage Development, H1 2016 21
Products under Development by Companies, H1 2016 22
Products under Development by Companies, H1 2016 (Contd..1) 23
Products under Development by Companies, H1 2016 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2016 25
Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016 26
Diarrhea - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016 27
Diarrhea - Pipeline by Actelion Ltd, H1 2016 28
Diarrhea - Pipeline by Aegis Therapeutics, LLC, H1 2016 29
Diarrhea - Pipeline by Akthelia Pharmaceuticals Limited, H1 2016 30
Diarrhea - Pipeline by AlbireoPharma, H1 2016 31
Diarrhea - Pipeline by Allergan Plc, H1 2016 32
Diarrhea - Pipeline by Anatara Lifesciences Limited, H1 2016 33
Diarrhea - Pipeline by Ardelyx, Inc., H1 2016 34
Diarrhea - Pipeline by Assembly Biosciences, Inc., H1 2016 35
Diarrhea - Pipeline by Chiesi Farmaceutici SpA, H1 2016 36
Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2016 37
Diarrhea - Pipeline by DesignMedix, Inc., H1 2016 38
Diarrhea - Pipeline by DiscoveryBiomed, Inc., H1 2016 39
Diarrhea - Pipeline by Genexine, Inc., H1 2016 40
Diarrhea - Pipeline by GlaxoSmithKline Plc, H1 2016 41
Diarrhea - Pipeline by GP Pharm, S.A., H1 2016 42
Diarrhea - Pipeline by Helsinn Healthcare S.A., H1 2016 43
Diarrhea - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 44
Diarrhea - Pipeline by Merck and Co., Inc., H1 2016 45
Diarrhea - Pipeline by Mucosis B.V., H1 2016 46
Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 47
Diarrhea - Pipeline by Novartis AG, H1 2016 48
Diarrhea - Pipeline by Pfizer Inc., H1 2016 49
Diarrhea - Pipeline by Prokarium Limited, H1 2016 50
Diarrhea - Pipeline by Protagonist Therapeutics Inc., H1 2016 51
Diarrhea - Pipeline by Rebiotix Inc., H1 2016 52
Diarrhea - Pipeline by RxBio, Inc., H1 2016 53
Diarrhea - Pipeline by Sanofi Pasteur SA, H1 2016 54
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2016 55
Diarrhea - Pipeline by Shire Plc, H1 2016 56
Diarrhea - Pipeline by Sigmoid Pharma Limited, H1 2016 57
Diarrhea - Pipeline by Summit Therapeutics Plc, H1 2016 58
Diarrhea - Pipeline by Synthetic Biologics, Inc., H1 2016 59
Diarrhea - Pipeline by Syntiron LLC, H1 2016 60
Assessment by Monotherapy Products, H1 2016 61
Number of Products by Stage and Target, H1 2016 63
Number of Products by Stage and Mechanism of Action, H1 2016 65
Number of Products by Stage and Route of Administration, H1 2016 67
Number of Products by Stage and Molecule Type, H1 2016 69
Diarrhea Therapeutics - Recent Pipeline Updates, H1 2016 140
Diarrhea - Dormant Projects, H1 2016 175
Diarrhea - Dormant Projects (Contd..1), H1 2016 176
Diarrhea - Dormant Projects (Contd..2), H1 2016 177
Diarrhea - Discontinued Products, H1 2016 178

List of Figures
Number of Products under Development for Diarrhea, H1 2016 13
Number of Products under Development for Diarrhea - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Investigation by Universities/Institutes, H1 2016 18
Comparative Analysis by Late Stage Development, H1 2016 19
Comparative Analysis by Clinical Stage Development, H1 2016 20
Comparative Analysis by Early Stage Products, H1 2016 21
Assessment by Monotherapy Products, H1 2016 61
Number of Products by Top 10 Targets, H1 2016 62
Number of Products by Stage and Top 10 Targets, H1 2016 62
Number of Products by Top 10 Mechanism of Actions, H1 2016 64
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 64
Number of Products by Routes of Administration, H1 2016 66
Number of Products by Stage and Routes of Administration, H1 2016 66
Number of Products by Top 10 Molecule Types, H1 2016 68
Number of Products by Stage and Top 10 Molecule Types, H1 2016 68

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2016

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) ...

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Acyl CoA Desaturase ...

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Pipeline Review, H2 2016

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

ATP Binding Cassette Sub Family A Member 1 (ATP Binding Cassette Transporter 1 or ABC 1 or ATP Binding Cassette 1 or Cholesterol Efflux Regulatory Protein or ABCA1) - Pipeline Review, H2 2016 Summary Global ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.